NTRACRANIAL metastases account for most malignant brain tumors. There are an estimated 170,000 new cases of brain metastases in the US every year, based on approximately 12.5% of patients with systemic cancer that spreads to the brain and an occurrence rate of 1,284,000 new cases of cancer per year.
trol, thereby reducing mass effect and clinical symptoms, and provides tissue for pathological examination. Data from well-designed prospective studies have established the survival benefit and prolongation of functional independence after resection of a single brain metastasis, 15, 23 particularly in patients without active systemic cancer and who have a good performance status (typically defined as a KPS 9 score of Ն 70). In one prospective randomized trial of resection and WBRT compared with biopsy procedure and WBRT for a single brain metastasis, the median survival time was 40 weeks in the patients who had undergone resection plus WBRT as opposed to 15 weeks in those who had received WBRT only. 15 Functional independence lasted significantly longer (38 weeks) in those who had undergone surgery compared with those in the radiation-only arm (8 weeks) . Results of another prospective randomized trial by Vecht, et al., 23 confirmed these findings. The benefit of WBRT after surgical removal is less clear. In the only randomized prospective study of single metastasis in which resection plus postoperative WBRT had been compared with surgical removal without postoperative WBRT, the authors found no survival advantage with the addition of radiation.
14 There was also no difference in the duration of functional independence (37 weeks). However, patients in the postsurgical observation arm only (no postsurgical WBRT) had a much higher incidence of local tumor recurrence (46 compared with 10%) as well as distant brain tumor recurrence (37 compared with 14%) and a shorter time to tumor recurrence. There was also a higher incidence of death related to neurological causes in the observation cohort (44%) as compared with the surgery plus WBRT group (14%). Considering these data, treating single lesions with aggressive local radiation therapy after surgery and withholding WBRT may be good options for appropriately selected patients. Such an approach would delay or avoid altogether the potential acute and delayed adverse effects of WBRT.
Brachytherapy is a form of localized radiation treatment that involves the delivery of highly localized doses of radiation implanted in the tumor site while minimizing the dose to surrounding tissue. Applying brachytherapy to the resection margins is logical after resecting a single metastasis, given the high rate of local recurrence of these lesions. The GliaSite RTS (Cytyc Surgical Products II, Mountain View, CA) is a single-applicator system that provides a conformal and relatively uniform dose to the resection cavity, the area with the typically highest risk for recurrence in patients with metastatic brain tumors. In this paper we report the first experience with GliaSite brachytherapy-and the only prospective trial of brachytherapy-for brain metastasis.
Clinical Material and Methods

Trial Design
Between August 2001 and April 2003, 13 institutions enrolled patients in a phase II clinical trial designed to evaluate the effectiveness of the GliaSite RTS for the delivery of local brachytherapy to the resection cavity in patients with single metastatic tumors. The GliaSite RTS device consists of a silicone variable-volume balloon catheter and a subcutaneous access port that allows for the infusion and retrieval of fluids in the balloon. The balloon is placed in the resection cavity immediately after tumor removal (Fig. 1) . The primary study end point was the 1-year local control rate. The secondary end points included survival, incidence of distant recurrence, QOL, and treatment toxicity. The institutional review board at each participating institution reviewed and approved the study protocol, and patients gave written informed consent. The study was monitored to ensure completeness and accuracy of the data. WorldCare Clinical Trials, Inc. (Cambridge, MA), provided an independent, central MR imaging review of patients who had completed brachytherapy.
Patient Eligibility Criteria
Patients who fulfilled the following criteria were eligible to participate in the study: a single, newly diagnosed, resectable supratentorial metastatic brain tumor documented on contrast-enhanced MR imaging; histological evidence of metastatic tumor on the final pathological report; an age of 18 years or older; a KPS score of 70 or greater; a life expectancy of at least 3 months; and no serious concurrent infection or other medical illness that would jeopardize the ability of the patient to participate safely in the study. Exclusion criteria consisted of histological characteristics of lymphoma or small cell lung cancer, previous or planned treatment of the metastatic brain tumor, radiation of any kind previously applied to the brain, and pregnancy.
Administered Treatment
After maximum resection of the single metastasis, an appropriately sized GliaSite balloon catheter was selected to ensure adequate filling of the resection cavity and was implanted. The selected balloon size was the closest to, but less than, the diameter of the resection cavity. Three balloon sizes are available: 2, 3, and 4 cm. The respective minimum and maximum fill volumes are 4 to 5, 5 to 15, and 15 to 35 ml. Once the GliaSite device was implanted, it was filled with the appropriate fill volume of a nonionic x-ray film contrast medium solution to ensure satisfactory balloon filling and proper placement. A mixture of 75% sterile normal saline to 25% nonionic contrast agent was recommended for injection. Within 48 hours of the craniotomy, MR images with and without contrast were obtained to evaluate the integrity and placement of the applicator and to provide data necessary to complete brachytherapy planning. The baseline image was also evaluated for postoperative enhancement, cerebral edema, and hemorrhage. A maximum 1-cm rim of residual enhancement was allowed. This image served as the baseline from which all subsequent images were compared.
Plain skull x-ray films were obtained to assess the inflation size, shape, and location of the balloon and access port, and standard brachytherapy planning was conducted. The prescription dose for each patient was a total dose of 60 Gy at a 1-cm depth to be delivered at a rate of 40 to 60 cGy/ hour. Brachytherapy was planned to begin within 21 days of surgery. Twenty-four hours before starting brachytherapy, the patient began taking Lugol iodine solution or supersaturated potassium iodide to decrease the potential for the accumulation of iodine 125 in the thyroid. This agent was continued until 24 hours after completing the brachytherapy. The radiation source was Iotrex (Cytyc Surgical Products II), an aqueous iodine-125 radiotherapy solution. Be-fore infusing the Iotrex, the contrast agent in the GliaSite device was removed. The prescribed dose of Iotrex was infused percutaneously, and saline was injected to complete the fill volume. After completion of the prescribed dwell time, the Iotrex and saline solution was retrieved, and device removal was planned.
Evaluation and Criteria for Treatment Response
Patients returned for a follow-up evaluation at 1 month and 3 months after the completion of brachytherapy and every 3 months thereafter until death, for a minimum of 1 year and up to 2 years in surviving patients. All follow-up visits included MR imaging studies with and without contrast. The 1-month posttreatment MR image was obtained to assess possible early radiation effects. In addition, a physical examination was performed, including a neurological examination, steroid medication assessment, KPS scoring, MMSE 6 to measure global cognitive function, FACT-BR 24 to measure a patient's self-reported QOL, and collection of adverse event information. The volume of enhancement on follow-up MR images was compared with that on the 48-hour postoperative image to assess local control. If at any time symptoms suspicious for brain disease progression or treatment toxicity developed in a patient, an MR image was obtained. Toxicities were reported and graded in accordance with the systemic and CNS toxicity ratings based on the Common Toxicity Criteria (version 2.0; National Cancer Institute, National Institutes of Health, Bethesda, MD). Synergos, Inc. (The Woodlands, TX), an independent contract research organization, conducted quality assurance audits of the study data at each of the participating centers. All data were 100% source verified by reviewing the patient medical records to corroborate data listed on case report forms.
"Local recurrence" was defined as new or increased contrast enhancement within the treatment volume. "Local control" was defined as the absence of, or stable, contrast enhancement on MR imaging within the treatment volume and a stable or decreased dose of steroid agents at the time of imaging. Indeterminate cases did not fit either category. By using histological evidence (if a patient's clinical condition permitted a biopsy procedure or resection) or fluorodeoxyglucose PET and/or MR spectroscopy findings, attempts were made to distinguish local tumor from radiation necrosis when an MR image showed new or increased enhancement. Magnetic resonance images were also evaluated for cerebral edema, hemorrhage, midline shift, and necrosis. At each clinical follow-up evaluation and MR imaging session, the local investigator assessed local recurrence and treatment toxicity. A subsequent central neuroradiology review (WorldCare Clinical, Inc.) was performed to aid in discriminating tumor recurrence from radiation effects, because these disease entities have similar imaging features. All available MR images were subjected to central review for serial quantitative analysis of the volume of enhancement, which was calculated using hand-drawn region-of-interest measurements performed on Gd-enhanced T 1 -weighted MR imaging sequences by using proprietary licensed software (Cheshire, version 4.4; Parexel, Inc., Waltham, MA). Care was taken to exclude any nonenhancement-related T 1 bright signal (such as signal related to subacute hemorrhage) from enhancing volume measurements by comparing and subtracting unenhanced and enhanced T 1 sequences. Central excavations or necrotic cavities within enhancing lesions were also excluded from the volume measurement. Figure 2 shows the method of volumetric measurement. Table 1 shows the methods used for response determination. Based on volumetric assessment, local control was defined as a stable, declining, or low volume of enhancement in the treatment bed. Stability had to be present over at least three successive observations to warrant that classification. Figure 3 features an example of stable disease. An incline-decline pattern in the volume of enhancement is included in this group. "Low volume" was arbitrarily defined as less than 2 ml of enhancement. Local recurrence was volumetrically defined as increasing enhancement in the treatment bed. Unclassifiable cases did not fit into either local control or recurrence groupings, often because of insufficient time points to permit classification. The initial volumetric assessment of local control or recurrence, based on stable as opposed to progressively enhancing volumes, was modified when histological evidence to the contrary became available. Unclassifiable cases were assigned to the local control group or the treatment failure group based on histological features, when such data were available.
Treatment was considered to have failed in patients with local recurrence on MR imaging, and such patients were removed from the study. Further treatment was administered at the discretion of the treating physician, and these patients were followed up for survival data. If the patient had distant brain recurrence together with local control, he or she remained in the study for further evaluation of the local control. Additional treatment for distant recurrence was administered at the discretion of the treating physician.
The cause of death was classified as CNS or non-CNS in nature. The CNS classification consisted of neurological causes of death, including tumor progression at the site of resection and brachytherapy, toxicity associated with resection or brachytherapy, distant recurrence in the brain, or any other brain cause. The non-CNS designation included systemic causes of death, including disease progression outside the brain or other systemic processes.
Statistical Analysis
The sample size was selected to provide a strong estimate of the local control rate at 1 year posttreatment. If an underlying binomial population with a mean of 80% is assumed, then a sample size of 62 patients is required to have an expected 95% CI with a precision of approximately 10% (95% CI 70-90%). Seventy-one patients were enrolled in the study, 62 received implants, and only 54 actually received brachytherapy. With a sample size of 54 patients and the same confidence level, the 95% CI has a precision of approximately 11% (95% CI 69-91%).
The proportion of patients with local control at 1 year posttreatment was determined, and a 95% CI was applied. In addition, the Kaplan-Meier method was used to further investigate the proportion of patients with local control at any particular time point. Patients were censored if they died of causes without a local recurrence. Proportional hazard methods were used to determine factors affecting local recurrence and patient survival. Summaries of patient survival and time to distant metastasis or recurrence were also analyzed using the Kaplan-Meier method. Quality of life and cognitive function (KPS, MMSE, and FACT-BR total and subscales) were evaluated with descriptive statistics. Paired t-tests or, in some cases, the Wilcoxon signed-rank test, were used to investigate changes from baseline in the various QOL assessments. Survival was determined from the date of surgery.
Safety was evaluated by tabulating adverse events: overall, by maximum severity, and by the strongest relationship to GliaSite brachytherapy. In addition, the following breakdowns were tabulated: nonserious events unrelated to therapy, nonserious events related to therapy, serious events unrelated to therapy, and serious events related to therapy.
The following variables were evaluated to determine whether any potential prognostic factors for patient survival could be determined: balloon size, patient age, patient sex, tumor location, primary tumor site, presence of primary tumor at the time of treatment, presence of extracranial metastasis at the time of treatment, baseline KPS score, maximum cross-sectional diameter of the tumor, tumor volume, duration of time between the diagnosis of the primary tumor and the development of brain metastasis, whether radiation necrosis was experienced, and whether the patient had any additional treatment after the GliaSite RTS. To develop the multivariate model, each potential prognostic factor was initially tested in a univariate model. Cox proportional hazards methods were used to determine whether the characteristic of interest played a statistically significant role in predicting either local recurrence or patient survival. The Cox regression allowed for the analysis of time-dependent covariates in the model.
Results
Patient and Tumor Characteristics
Seventy-one patients were enrolled in the study between August 2001 and April 2003. Among these patients, nine did not have the GliaSite balloon catheter placed for the following reasons: ineligible pathological entity (six patients), cerebral edema (two patients), or preoperative myocardial infarction (one patient). Sixty-two patients consisting of 38 men and 24 women with an age range of 29 to 86 years (median age 60 years) underwent implantation of the balloon catheter. The most common underlying tumor was non-small cell lung cancer (47% tumors). Other tumor types included gastrointestinal (eight); melanoma (seven); renal (four); unknown primary (three); sarcoma (three); and cervical (two), breast (two), head and neck (two), and bladder carcinoma (one). In one patient, no systemic cancer was present. The only site of metastasis was the brain in 36 patients (58%). The tumor was located in the frontal lobe in 18 patients (29%), parietal lobe in 13 (21%), occipital lobe in eight (13%), temporal lobe in eight (13%), and in a combination of lobes in 13 (21%). Two were situated in the cerebellum. The preoperative contrast-enhancing tumor ). The baseline KPS score ranged from 70 to 100 (median 90); MMSE score, from 16 to 30 (median 28.5); and FACT-BR score, from 69 to 175 (median 132). Eight patients did not receive brachytherapy after balloon implantation because of an ineligible pathological entity (two patients), cerebral edema (one patient), coagulopathy (one patient), cardiopulmonary arrest (one patient), second metastatic lesion revealed on postoperative MR imaging (one patient), cerebral bleeding (one patient), and tumor close to the optic nerve (one patient). Six of these patients were excluded from the study at 0 to 33 days (median 3.5 days) from surgery and were censored on the study exit date. Two others died 3 and 5 days after surgery. The primary and secondary outcome measures in the subsequent analysis focus predominantly on the 54 patients who received the GliaSite catheter and brachytherapy (hereafter referred to as "treated patients"). Table 2 shows the clinical and tumor characteristics in the treated patients. Tumor was located in the right cerebral hemisphere in 30 patients and the left cerebral hemisphere in 22. The tumor involved more than one lobe in 12 patients: frontoparietal in four; parietotemporal in four; and the frontotemporal, temporooccipital, parietooccipital, and frontoparietotemporal lobes in one patient each. Two patients with cerebellar tumors were actually ineligible for study inclusion but were treated according to the protocol by the local investigators and were included in the analysis. In the combined intent-to-treat and treated groups the preoperative cross-sectional tumor diameter measured 1.5 to 7 cm (median 3 cm), and the postoperative cross-sectional tumor cavity diameter ranged from 1 to 5.9 cm (median 2.5 cm).
Implantation and Radiation Delivery
The implanted balloon size was 2 cm in 37 patients, 3 cm in 20, and 4 cm in five. Among the 54 treated patients, a
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GliaSite brachytherapy in brain metastases 379 FIG. 3. Gadolinium-enhanced T 1 -weighted MR images representing an example of a typical stable case. A: The preoperative state. B: Postoperative images with the GliaSite balloon device in place for 48 hours (0.9 ml). C: One-month posttreatment images with the balloon removed (6.5 ml). D: At 3 months posttreatment (5.6 ml). E: At 6 months posttreatment (4.7 ml). F: Nine months (5.6 ml) after the procedure. Enhancing volume is given in parentheses for each time point.
2-cm balloon was placed in 33 (61%), a 3-cm balloon in 17 (32%), and a 4-cm balloon in four (7%). There were no reported surgical complications attributed to device placement. Nine patients received less than the minimum fill volume initially administered at the time of surgery because of cerebral edema but subsequently received additional volume before brachytherapy once the cerebral edema had subsided. The median final delivered dose was 60 Gy (range 56-64 Gy), prescribed to 1 cm in all patients. The median dwell time was 114 hours (range 93-162 hours). The median net administered activity was 213 mCi (range 154-440 mCi). Six devices were not explanted after completion of the brachytherapy; four patients refused and the treating physician decided in two patients.
Local Control
As assessed on MR imaging and reported by the sites, the crude rate of local control in the treated group was 83% (45 of 54 patients). The actuarial 1-year local control rate was 79%, and the median local control time was greater than 66 weeks. In the nine patients (17%) with local recurrence, the interval from surgery to relapse ranged from 5 to 66 weeks (median 26 weeks). Among these nine patients, four were then treated with WBRT and one underwent SRS. Six of the nine patients underwent a reoperation, primarily because they were symptomatic. Four patients had tumor progression confirmed on pathological analysis, and in two of them the tumor was mixed with radiation necrosis. Two other patients had radiation necrosis without tumor. If two patients with pure radiation necrosis are no longer classified as having a local recurrence, the resultant site-assessed local control rate is 87% (47 of 54 patients). Based on the central neuroradiology review combined with the reoperation data, the local control rate is 82% (44 of 54 patients).
Magnetic resonance spectroscopy or PET studies were obtained in 13 patients and showed changes of an indeterminate nature (five patients), tumor (four patients), mixed tumor and necrosis (three patients), and necrosis (one patient). Five of these patients underwent repeated resection, and each had radiation necrosis; in one patient, the necrosis was mixed with tumor. The histological data correlated with the PET or MR spectroscopy findings in only two of five cases.
Distant Recurrence
Distant recurrence occurred in 24 of the treated patients (44%), and the actuarial 1-year distant control rate was 50%. Distant recurrence with local control occurred in 20 patients (37%). Distant and local recurrence occurred in four patients (7%). The median time to distant recurrence was 54 weeks (95% CI 26-indeterminate). Sixteen of 24 patients received treatment for a distant brain recurrence, including WBRT alone (seven patients), SRS alone (four patients), SRS with WBRT (two patients), chemotherapy with WBRT (one patient), resection with WBRT (one patient), and resection with SRS (one patient).
Patient Survival
The median survival in treated patients was 40 weeks (95% CI 31-60), and the actuarial 1-year survival rate was 40%. Thirty-five percent of treated patients with a 12-month minimum follow-up evaluation were alive. The Kaplan-Meier survival curve for the treated patients is presented in Fig. 4 . Of the 35 treated patients who died, 31 died of non-CNS causes, including systemic disease progression outside of the brain in 24 (69%) and multiorgan failure, suicide, perforated bowel, sudden death unrelated to the brain, cardiopulmonary arrest, general medical decline, and probable pulmonary embolism in one patient each. Deaths were CNS-related-that is, due to distant recurrence in the brain-in four patients (11%).
Three variables were significant in univariate and multivariate survival models: the presence of extracranial metastasis (p = 0.02, RR 2.46), a larger preoperative tumor size (p Ͻ 0.01, RR 1.62), and the presence of radiation necrosis without tumor on resection (p = 0.02, RR 0.16) were the most significant factors associated with patient survival. The median survival in patients with radiation necrosis was 83 weeks compared with 35 weeks in those without necrosis. 
Quality-of-Life Measures and Cognitive Function
The median time of functional independence based on a KPS score greater than or equal to 70 was 40 weeks (95% CI 29-83) when the KPS score was considered 0 at death. Using a methodology in which patients were censored at the time of their last reported KPS score, the median time of functional independence was 53 weeks (95% CI 40-indeterminate). There was no change in the median MMSE score of 29 at baseline and at 6 months posttreatment in those tested (26 of 39 patients who were alive and tested) and at 12 months posttreatment (13 of 24 patients who were alive and tested). Eight patients were removed from the study because of suspected local recurrence, and data were not available in another three. The median total FACT-BR score in this same group of patients decreased from 130 at baseline to 112 at 1-year posttreatment (p = 0.30, Wilcoxon signed-rank test). Thirteen of 39 patients alive at 6 months posttreatment and six of 24 patients alive at 12 months posttreatment were taking steroid agents at a mean daily dose of 6 and 9 mg of dexamethasone, respectively.
Treatment-Related Toxicities
Increased enhancement attributed to a radiation effect was seen on studies obtained in 36 (80%) of 46 patients who had undergone 1-month posttreatment MR imaging (Fig.  3C) . The primary serious adverse event related to the device was radiation necrosis. Among 13 patients who underwent a reoperation for symptomatic imaging changes and/ or an increase in contrast enhancement and in whom recurrent tumor or radiation necrosis was suspected, radiation necrosis without tumor was found in nine (17% incidence). Radiation necrosis mixed with tumor was found in two other patients. The actuarial 1-year incidence of radiation necrosis without tumor was 23%. According to logistic regression analysis, there was no correlation between the balloon size, surface dose, or radiation treatment volume, and the occurrence of radiation necrosis. Table 3 shows the adverse events by grade in the treated patients.
Discussion
Brachytherapy is an attractive alternative to WBRT after the resection of a single brain metastasis because it targets the most frequent site of tumor recurrence, the resection cavity, while eliminating the treatment time and potential acute, subacute, and delayed adverse effects of WBRT, which can reduce QOL and cognitive function. 5 One approach to a single brain metastasis is to withhold WBRT if adequate local control can be achieved, reserving WBRT, SRS, or chemotherapy until the time of recurrence. 12 In contrast to malignant gliomas, there is limited data on brachytherapy for brain metastasis. In the largest series reported on to date, iodine-125 seed brachytherapy alone for newly diagnosed brain metastasis resulted in a median patient survival of 17 months; 13 the majority of these patients had a single metastasis. Authors of reports on smaller numbers of patients with recurrent or newly diagnosed metastatic tumors have indicated survivals ranging from 6 to 26 months. 2, 3, 17, 19 The present study represents the first prospective trial of brachytherapy for brain metastasis using the GliaSite RTS.
The GliaSite brachytherapy system has potential advantages over conventional brachytherapy with iodine-125 seeds or indium strands. The balloon fills the tumor resection cavity and provides a conformal and relatively homogeneous dose distribution, avoiding the multiple "hot" and "cold" spots that may occur with seed and strand brachytherapy. 10, 11 In addition, the dosimetry is precise and easily reproduced. Because most metastases are spherical, they provide excellent geometry for balloon conformity. The GliaSite device is placed at the time of resection, thus avoiding the sequential placement of a stereotactic head frame, multiple scalp incisions, and bur holes and the movement of seed applicators through functioning brain tissue, which occurs during placement of the radioactive sources or the afterloading catheters. In a phase I trial of GliaSite for the treatment of recurrent primary brain tumors, the safety and performance of the device were demonstrated, and brain conformance to the device was excellent in all patients. 22 The GliaSite RTS device received Food and Drug Administration clearance in 2001 for the treatment of resected malignant brain tumors.
The local control rate on MR imaging after resection and GliaSite brachytherapy was 82 to 87%, as determined using several methods, and is similar to the 80 to 90% rate ob-tained with resection and WBRT, which was reported by Patchell and colleagues. 14, 15 The median time to local recurrence after GliaSite treatment was greater than 66 weeks, which is similar to the more than 52 and 59 weeks with surgery plus WBRT 14, 15 and much longer than the 27 weeks with surgery alone, as reported by Patchell, et al., 14 thus suggesting that resection plus brachytherapy is an effective method of achieving local control in patients with a single brain metastasis. Although a direct comparison with SRS cannot be made because of the potentially different patient populations and selection factors, the local control rate with brachytherapy and resection is very similar to the mean rate of 83% with SRS for brain metastasis, as reported by Boyd and Mehta 4 in a review of 21 published studies that included more than 2700 patients.
The median survival time of 40 weeks (95% CI 31-60) with an actuarial 1-year survival rate of 40% in the treated patients in the present study compares favorably with historical controls. 14, 15, 23 Three factors were significantly associated with patient survival, including the presence of extracranial metastasis, which has been demonstrated in Radiation Therapy Oncology Group brain metastasis trials. 8 The other two factors for survival were tumor size and radiation necrosis. Tumor size has not been previously identified as a survival factor in surgical trials for a single metastasis. Radiation necrosis is an expected complication of high-dose local radiation to the brain and is reported in up to 50% of patients receiving SRS or brachytherapy for primary or metastatic tumors. [2] [3] [4] [17] [18] [19] 25 Forsyth and colleagues 7 noted better survival proportionate to the degree of radiation necrosis in patients whose history included radiation administered for a primary brain tumor and who were undergoing biopsy for a new enhancing lesion suspected to be a tumor recurrence or radiation necrosis.
The most relevant factor in survival in patients with brain metastasis may not be overall survival but survival that is free of neurological signs. Among the 35 treated patients who died in the present study, only four deaths (11%) were attributed to a neurological cause. This rate is similar to that in the study by Patchell, et al., 14 who reported that 14% of patients in the resection plus WBRT group died of neurological causes. The median time from implant to distant brain recurrence was 54 weeks (95% CI 26-indeterminate). These data are similar to those in other studies in the literature in which patients with brain metastasis were treated with surgery or SRS alone (no WBRT). 14, 20, 21 If the KPS score is considered 0 at death and is not censored, the median time that the KPS score remained 70 or greater is 40 weeks. This method assumes that there was a gradual decline in the KPS score before death, and this conclusion is not valid in several of the patients in whom the cause of death was a sudden non-CNS type, suicide, perforated bowel, cardiopulmonary arrest, or probable pulmonary embolus. When the KPS was censored at the date of the last score, the median time that the KPS score remained 70 or greater was 53 weeks. Either method of determining the duration of functional independence showed that the duration was very favorable, compared with this parameter in trials of resection and WBRT (range 30-38 weeks). 14, 15, 23 The identification of radiation necrosis in the present trial differs from that in the phase I study of GliaSite brachytherapy in patients with recurrent malignant glioma because no patient with radiation necrosis was identified in the glioma trial. There are important differences between these two studies. First, the glioma trial was smaller (21 patients) and was not specifically designed to systematically monitor this toxicity. In addition, the volumes of the resection cavities in the glioma trial were significantly larger. Three-or 4-cm balloons were used in 18 of the 21 patients. In contrast, 2-cm balloons were used in 61% of the patients with metastasis. One intuitive contributing factor is the surface dose based on balloon size: the median surface dose in the glioma study was 169 Gy (range 79-246 Gy) compared with 314 Gy (range 203-354 Gy) in the present study. Note, however, that there was no difference in the surface dose or treatment volume between those with and those without radiation necrosis in the patients with metastasis.
The temporal pattern of enhancement on MR imaging may assist in distinguishing between radiation effect and tumor recurrence. A plateau or decline in the volume of enhancement, even if the decline was preceded by an increase in enhancement, may suggest radiation effect, as indicated by our experience and post-SRS imaging changes. 16 A much smaller percentage of patients than those who showed early enhancement required reoperation because of symptoms. We suggest that the majority of patients with imaging changes after brachytherapy can be closely monitored and undergo surgery only if appropriate to the clinical situation and before additional radiation therapy is administered to the site. Radiation necrosis cannot be reliably distinguished from tumor recurrence on MR imaging, MR spectroscopy, or PET.
When selecting SRS or GliaSite brachytherapy to treat a single brain metastasis, the following considerations apply. The administration of GliaSite is preceded by resection, which involves gross removal of the metastasis. Resection also immediately reduces mass effect, thereby often decreasing clinical symptoms, and provides tissue for the histological diagnosis of the metastasis. GliaSite can also be used to treat lesions that are too large for SRS (typically Ͼ 3 cm). In the present trial, 40% of patients had a preoperative tumor diameter greater than 3 cm and may not have been eligible for SRS. There is no absolute upper limit in the size of the preoperative tumor because the brain collapses around the resection cavity when the lesion is completely removed. GliaSite brachytherapy can also be used at institutions that do not have SRS capability. GliaSite can- not be used for lesions smaller than 2 cm. Neither SRS nor brachytherapy should be used when the tumor is close to the optic nerve and/or chiasm or the brainstem.
Conclusions
GliaSite brachytherapy was safe, effective, and well tolerated after resection of a single brain metastasis without the administration of WBRT. Local control in the present study was comparable with that in historical studies in similar patient populations in whom surgery and then WBRT or SRS were performed. Furthermore, functional independence was preserved. Brachytherapy represents a means of providing aggressive local treatment for a single brain metastasis and delaying WBRT or other treatments until the time of local or distant brain recurrence. Only a randomized trial in which resection followed by GliaSite brachytherapy is compared with resection followed by WBRT in patients with a single brain metastasis will allow for a direct comparison of the efficacy and tolerability of these treatments. In the present trial additional follow-up evaluations will be performed at 2 years posttreatment. The most significant toxicity in this trial was radiation necrosis. Strategies to decrease the incidence of radiation necrosis included lowering the total brachytherapy dose (Ͻ 60 Gy) and/or prescribing to a shallow depth (Ͻ 1 cm). In an ongoing trial of GliaSite brachytherapy for brain metastasis, the same total brachytherapy dose (60 Gy) administered at a prescription depth of 0.5 cm is being tested.
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